GGrantIndex
← Search

Determining the Impact of Semisynthetic Saponin Immunologic Adjuvant Titerquil-1055 on Influenza Vaccine Immunogenicity and Stability

$223,002N43FY2017AINIH

Adjuvance Technologies, Inc., New York NY

Investigators

Philip Livingstoncontact

Abstract

The Contractor will develop TiterQuil-1055, a semi-synthetic saponin adjuvant analog of QS-21, for the purpose of improving the immunogenicity of commercially available flu vaccines (Fluzone (Sanofi Pasteur), Fluvirin (Seqirus), and Flublok (Protein Sciences)).

View original record on NIH RePORTER →
Determining the Impact of Semisynthetic Saponin Immunologic Adjuvant Titerquil-1055 on Influenza Vaccine Immunogenicity and Stability · GrantIndex